• Cumberland Pharmaceuticals swung to third-quarter 2026 net income of $77.78 million, including a gain from its asset divestiture.
• Total revenue rose to $2.16 million from a year earlier.
• The $100 million strategic transaction with Apotex closed July 1, strengthening the balance sheet and allowing greater focus on clinical development.
• Plans include submitting an FDA application for ifetroban to treat DMD-associated cardiomyopathy; the agency granted rolling review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611101600PR_NEWS_USPR_____CL94524) on November 10, 2026, and is solely responsible for the information contained therein.